Top 24 Alzheimer's Disease treatment startups in USA
Apr 09, 2026
|
Like
23
1
Funding: $2.4B
Arrowhead Research has created the Arrowhead TRiM drug discovery and development platform that utilizes a suite of RNA interference (RNAi) delivery technologies, chemistry, structures, and manufacturing technologies. REDEMPLO (plozasiran) is the company's lead (FDA-approved) siRNA-based drug used to significantly lower triglyceride levels in adults with familial chylomicronemia syndrome (FCS). Arrowhead is also conducting clinical trials for drugs against coronary artery disease, atherosclerotic cardiovascular disease, obesity, COPD, idiopathic pulmonary fibrosis, Alzheimer's disease, Huntington's disease, alpha-1 antitrypsin deficiency and hepatitis B.
Arrowhead Research has created the Arrowhead TRiM drug discovery and development platform that utilizes a suite of RNA interference (RNAi) delivery technologies, chemistry, structures, and manufacturing technologies. REDEMPLO (plozasiran) is the company's lead (FDA-approved) siRNA-based drug used to significantly lower triglyceride levels in adults with familial chylomicronemia syndrome (FCS). Arrowhead is also conducting clinical trials for drugs against coronary artery disease, atherosclerotic cardiovascular disease, obesity, COPD, idiopathic pulmonary fibrosis, Alzheimer's disease, Huntington's disease, alpha-1 antitrypsin deficiency and hepatitis B.
2
Funding: $1.1B
Neurodegenerative diseases are one of the largest medical challenges of our time. Denali Therapeutics is dedicated to defeating neurodegenerative diseases through rigorous therapeutic discovery and development.
Neurodegenerative diseases are one of the largest medical challenges of our time. Denali Therapeutics is dedicated to defeating neurodegenerative diseases through rigorous therapeutic discovery and development.
3
Funding: $614.6M
Neumora Therapeutics develops precision therapies for treatment of brain diseases. Its uses the propriety platform Precision Toolbox, which includes a suite of translational, medical and computational tools for information discovery, capable of applying precision medicine approaches. Its therapeutic portfolio includes seven programs for the treatment of neuropsychiatric disorders and neurodegenerative diseases (major depressive disorder, Alzheimer's disease, schizophrenia, and Parkinson's disease). Neumora's lead program, navacaprant, is a novel, highly selective kappa opioid receptor (KOR) antagonist nearing the end of development as a reliable monotherapy for the treatment of MDD. Navacaprant is an investigational, once-daily oral medication designed to modulate dopamine and reward signaling pathways, which play a critical role in the regulation of mood, cognition, reward and behavior.
Neumora Therapeutics develops precision therapies for treatment of brain diseases. Its uses the propriety platform Precision Toolbox, which includes a suite of translational, medical and computational tools for information discovery, capable of applying precision medicine approaches. Its therapeutic portfolio includes seven programs for the treatment of neuropsychiatric disorders and neurodegenerative diseases (major depressive disorder, Alzheimer's disease, schizophrenia, and Parkinson's disease). Neumora's lead program, navacaprant, is a novel, highly selective kappa opioid receptor (KOR) antagonist nearing the end of development as a reliable monotherapy for the treatment of MDD. Navacaprant is an investigational, once-daily oral medication designed to modulate dopamine and reward signaling pathways, which play a critical role in the regulation of mood, cognition, reward and behavior.
4
Funding: $448.5M
Amylyx Pharmaceutical is a pharmaceutical company that specializes in providing solutions on Alzheimer’s and other diseases of the brain.
Amylyx Pharmaceutical is a pharmaceutical company that specializes in providing solutions on Alzheimer’s and other diseases of the brain.
5
Funding: $374M
Voyager Therapeutics is a clinical stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS). Gene therapy has the potential to transform the treatment of CNS and other diseases by providing a one-time therapy that dramatically improves patients' lives.
Voyager Therapeutics is a clinical stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS). Gene therapy has the potential to transform the treatment of CNS and other diseases by providing a one-time therapy that dramatically improves patients' lives.
6
Funding: $366.2M
Alzheon is committed to developing innovative medicines for patients suffering from Alzheimer's disease and other neurological and psychiatric disorders. Our Alzheon’s drug development platform which comprises proprietary chemistries, robust clinical efficacy and safety datasets in patients and genetically-defined subpopulations, and the ability to optimize molecules to have the desired therapeutic attributes.
Alzheon is committed to developing innovative medicines for patients suffering from Alzheimer's disease and other neurological and psychiatric disorders. Our Alzheon’s drug development platform which comprises proprietary chemistries, robust clinical efficacy and safety datasets in patients and genetically-defined subpopulations, and the ability to optimize molecules to have the desired therapeutic attributes.
7
Funding: $360M
LEXEO Therapeutics develops gene therapy for the world's most devastating diseases
LEXEO Therapeutics develops gene therapy for the world's most devastating diseases
8
Funding: $319.5M
Alector is a hypothesis-driven, neurology-focused startup that’s pioneering the discovery and development of first-in-class, immuno-modulatory therapies for Alzheimer’s disease and other neurodegenerative disorders. We are combining state-of-the-art antibody technology and recent discoveries in neuro-immunology and human genetics to develop a broad platform of novel therapeutics that harness the immune system to fight dementia and neurodegeneration.
Alector is a hypothesis-driven, neurology-focused startup that’s pioneering the discovery and development of first-in-class, immuno-modulatory therapies for Alzheimer’s disease and other neurodegenerative disorders. We are combining state-of-the-art antibody technology and recent discoveries in neuro-immunology and human genetics to develop a broad platform of novel therapeutics that harness the immune system to fight dementia and neurodegeneration.
9
Funding: $295.1M
Acumen Pharmaceuticals is focused on discovering and developing best in class therapeutics and diagnostics for Alzheimer’s disease.
Acumen Pharmaceuticals is focused on discovering and developing best in class therapeutics and diagnostics for Alzheimer’s disease.
10
Funding: $257.4M
Codiak Biosciences is developing multiple platforms for both therapeutic and diagnostic applications based on a growing appreciation for exosome biology.
Codiak Biosciences is developing multiple platforms for both therapeutic and diagnostic applications based on a growing appreciation for exosome biology.
11
Funding: $247M
Quince Therapeutics is developing novel treatments for altering the course of Alzheimer's and other degenerative diseases.
Quince Therapeutics is developing novel treatments for altering the course of Alzheimer's and other degenerative diseases.
12
Funding: $216.8M
Cognito is developing a therapeutic device, Spectris, which can be prescribed by doctors and used by patients at home to treat Alzheimer's disease by stimulating coordinated neural activity through non-invasive visual and auditory stimulation. The device is designed as a full-size headphones. The pivotal clinical study, which is evaluating Spectris AD therapy for Alzheimer's disease, is currently underway, and the company is preparing to submit an application to the FDA.
Cognito is developing a therapeutic device, Spectris, which can be prescribed by doctors and used by patients at home to treat Alzheimer's disease by stimulating coordinated neural activity through non-invasive visual and auditory stimulation. The device is designed as a full-size headphones. The pivotal clinical study, which is evaluating Spectris AD therapy for Alzheimer's disease, is currently underway, and the company is preparing to submit an application to the FDA.
13
Funding: $186M
BioXcel Therapeutics is a clinical stage biopharmaceutical company that utilizes novel artificial intelligence, or AI, to identify the next wave of medicines across neuroscience and immuno-oncology.
BioXcel Therapeutics is a clinical stage biopharmaceutical company that utilizes novel artificial intelligence, or AI, to identify the next wave of medicines across neuroscience and immuno-oncology.
14
Funding: $180M
Vigil Neuroscience is a biotechnology company that develops novel therapeutics for neurodegenerative diseases.
Vigil Neuroscience is a biotechnology company that develops novel therapeutics for neurodegenerative diseases.
15
Funding: $134.1M
We use genomic data to find better drugs, faster. We find new cures for brain diseases 1000X more cheaply and quickly using our proven network algorithms.
We use genomic data to find better drugs, faster. We find new cures for brain diseases 1000X more cheaply and quickly using our proven network algorithms.
16
Funding: $86.9M
Vaccinex develops novel therapeutic antibodies for treatment of neurodegenerative diseases and cancer. Its drugs are based on the inhibition of semaphorin SEMA4D - potent biological effector believed to prevent immune infiltration and induce myeloid-derived suppressor cells in tumors, as well as trigger neuroinflammation through reactive gliosis in the brain. The company's lead drug candidate, pepinemab, blocks SEMA4D and has the potential to enhance immune activity against tumors and reprogram underlying pathogenic immune mechanisms that exacerbate damage in chronic neurological diseases such as Asheimer's disease and Huntington's disease. The company is also advancing candidates for the treatment of cervical, pancreatic and lung cancer. Vaccinex uses its proprietary ActivMAb drug discovery platform, which enables the discovery and development of highly selective antibodies with novel mechanisms of action against complex membrane proteins.
Vaccinex develops novel therapeutic antibodies for treatment of neurodegenerative diseases and cancer. Its drugs are based on the inhibition of semaphorin SEMA4D - potent biological effector believed to prevent immune infiltration and induce myeloid-derived suppressor cells in tumors, as well as trigger neuroinflammation through reactive gliosis in the brain. The company's lead drug candidate, pepinemab, blocks SEMA4D and has the potential to enhance immune activity against tumors and reprogram underlying pathogenic immune mechanisms that exacerbate damage in chronic neurological diseases such as Asheimer's disease and Huntington's disease. The company is also advancing candidates for the treatment of cervical, pancreatic and lung cancer. Vaccinex uses its proprietary ActivMAb drug discovery platform, which enables the discovery and development of highly selective antibodies with novel mechanisms of action against complex membrane proteins.
17
Funding: $60.4M
Neurotrack is a digital health company dedicated to the development of non-invasive cognitive health assessment tools that will enable earlier and more effective evaluation of patients who may be at risk for cognitive decline, and help advance research of treatments for cognitive diseases, including Alzheimer's. We are driven by the belief that cognitive decline and conditions like Alzheimer’s disease can be beaten if detected early. Our energy and passion goes into developing digital tools to facilitate groundbreaking change.
Neurotrack is a digital health company dedicated to the development of non-invasive cognitive health assessment tools that will enable earlier and more effective evaluation of patients who may be at risk for cognitive decline, and help advance research of treatments for cognitive diseases, including Alzheimer's. We are driven by the belief that cognitive decline and conditions like Alzheimer’s disease can be beaten if detected early. Our energy and passion goes into developing digital tools to facilitate groundbreaking change.
18
Funding: $40.3M
T3D Therapeutics is a company developing remedial therapeutics for Alzheimer’s disease and other CNS disorders.
T3D Therapeutics is a company developing remedial therapeutics for Alzheimer’s disease and other CNS disorders.
19
Funding: $24.7M
Altoida Medical Device (AMD) provides health care professionals objective measurements of cognitive performance.
Altoida Medical Device (AMD) provides health care professionals objective measurements of cognitive performance.
20
Funding: $21.2M
NeuroVision is developing a noninvasive, quick, and inexpensive retinal imaging test for the early detection and diagnosis of Alzheimer’s disease. Our proprietary technology allows us to image amyloid beta plaque (the hallmark sign of the disease) in the retina.
NeuroVision is developing a noninvasive, quick, and inexpensive retinal imaging test for the early detection and diagnosis of Alzheimer’s disease. Our proprietary technology allows us to image amyloid beta plaque (the hallmark sign of the disease) in the retina.
21
Funding: $14.4M
AgeneBio is developing innovative therapeutics for unserved patients afflicted with neurological and psychiatric diseases to preserve and restore brain function.
AgeneBio is developing innovative therapeutics for unserved patients afflicted with neurological and psychiatric diseases to preserve and restore brain function.
22
Funding: $10M
Telocyte focuses on the development of telomerase therapy to treat Alzheimer's disease.
Telocyte focuses on the development of telomerase therapy to treat Alzheimer's disease.
23
Preclinical stage MedTech company developing an early diagnostic and a device to prevent Alzheimer's disease
24
Iluminos Therapeutics creates compounds that have the potential to treat neurodegenerative disease, in particular Alzheimer’s disease.
★
See also:
